476 related articles for article (PubMed ID: 26068539)
1. Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view.
Barrios V; Escobar C
Expert Rev Cardiovasc Ther; 2015; 13(7):811-24. PubMed ID: 26068539
[TBL] [Abstract][Full Text] [Related]
2. Risk impact of edoxaban in the management of stroke and venous thromboembolism.
Hurst KV; O'Callaghan JM; Handa A
Vasc Health Risk Manag; 2016; 12():329-35. PubMed ID: 27563246
[TBL] [Abstract][Full Text] [Related]
3. Edoxaban: A direct oral anticoagulant.
Poulakos M; Walker JN; Baig U; David T
Am J Health Syst Pharm; 2017 Feb; 74(3):117-129. PubMed ID: 28122753
[TBL] [Abstract][Full Text] [Related]
4. Edoxaban: an update on the new oral direct factor Xa inhibitor.
Bounameaux H; Camm AJ
Drugs; 2014 Jul; 74(11):1209-31. PubMed ID: 25034361
[TBL] [Abstract][Full Text] [Related]
5. Implications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice.
Barrios V; Escobar C
Future Cardiol; 2016 Jul; 12(4):419-33. PubMed ID: 27121025
[TBL] [Abstract][Full Text] [Related]
6. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Ruff CT; Giugliano RP; Braunwald E; Morrow DA; Murphy SA; Kuder JF; Deenadayalu N; Jarolim P; Betcher J; Shi M; Brown K; Patel I; Mercuri M; Antman EM
Lancet; 2015 Jun; 385(9984):2288-95. PubMed ID: 25769361
[TBL] [Abstract][Full Text] [Related]
7. Edoxaban: A Novel Factor Xa Inhibitor for the Management of Non-valvular Atrial Fibrillation and Venous Thromboembolism.
Kubli KA; Snead JA; Cheng-Lai A
Cardiol Rev; 2016; 24(4):205-10. PubMed ID: 26991962
[TBL] [Abstract][Full Text] [Related]
8. Edoxaban: a new oral direct factor xa inhibitor.
Camm AJ; Bounameaux H
Drugs; 2011 Aug; 71(12):1503-26. PubMed ID: 21861537
[TBL] [Abstract][Full Text] [Related]
9. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
Raskob G; Cohen AT; Eriksson BI; Puskas D; Shi M; Bocanegra T; Weitz JI
Thromb Haemost; 2010 Sep; 104(3):642-9. PubMed ID: 20589317
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
Ruff CT; Giugliano RP; Antman EM; Crugnale SE; Bocanegra T; Mercuri M; Hanyok J; Patel I; Shi M; Salazar D; McCabe CH; Braunwald E
Am Heart J; 2010 Oct; 160(4):635-41. PubMed ID: 20934556
[TBL] [Abstract][Full Text] [Related]
11. Direct factor Xa inhibitor edoxaban: from bench to clinical practice.
Brekelmans M; Middeldorp S; Coppens M
Expert Rev Hematol; 2015 Dec; 8(6):707-25. PubMed ID: 26560872
[TBL] [Abstract][Full Text] [Related]
12. The Efficacy and Safety of Edoxaban for VTE Prophylaxis Post-Orthopedic Surgery: A Systematic Review.
AlHajri L; Jabbari S; AlEmad H; AlMahri K; AlMahri M; AlKitbi N
J Cardiovasc Pharmacol Ther; 2017 May; 22(3):230-238. PubMed ID: 27811198
[TBL] [Abstract][Full Text] [Related]
13. Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial.
Eisen A; Giugliano RP; Ruff CT; Nordio F; Gogia HS; Awasty VR; Henderson DA; Mercuri MF; Rutman H; Antman EM; Braunwald E
Am Heart J; 2016 Feb; 172():144-51. PubMed ID: 26856226
[TBL] [Abstract][Full Text] [Related]
14. Oral anticoagulation with edoxaban. Focus on current phase III clinical development.
Ahrens I; Bode C
Hamostaseologie; 2012; 32(3):212-5. PubMed ID: 22786687
[TBL] [Abstract][Full Text] [Related]
15. Edoxaban tosylate.
Am J Cardiovasc Drugs; 2011; 11(2):129-35. PubMed ID: 21446778
[TBL] [Abstract][Full Text] [Related]
16. Establishing Edoxaban's Role in Anticoagulation.
Guirguis E; Brown D; Grace Y; Patel D; Henningfield S
J Pharm Pract; 2016 Jun; 29(3):228-38. PubMed ID: 27169733
[TBL] [Abstract][Full Text] [Related]
17. Edoxaban for the prevention of stroke in patients with atrial fibrillation.
Cervantes CE; Merino JL; Barrios V
Expert Rev Cardiovasc Ther; 2019 Apr; 17(4):319-330. PubMed ID: 30897988
[TBL] [Abstract][Full Text] [Related]
18. [Hokusai-VTE: edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism].
Sprynger M
Rev Med Liege; 2013 Oct; 68(10):548-51. PubMed ID: 24298731
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial.
Fuji T; Wang CJ; Fujita S; Kawai Y; Nakamura M; Kimura T; Ibusuki K; Ushida H; Abe K; Tachibana S
Thromb Res; 2014 Dec; 134(6):1198-204. PubMed ID: 25294589
[TBL] [Abstract][Full Text] [Related]
20. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.
Raskob GE; van Es N; Segers A; Angchaisuksiri P; Oh D; Boda Z; Lyons RM; Meijer K; Gudz I; Weitz JI; Zhang G; Lanz H; Mercuri MF; Büller HR;
Lancet Haematol; 2016 Aug; 3(8):e379-87. PubMed ID: 27476789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
